{
    "clinical_study": {
        "@rank": "15097", 
        "arm_group": [
            {
                "arm_group_label": "Treatment-Sequence 1", 
                "arm_group_type": "Other", 
                "description": "Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.\nTreatment -Sequence 1 : Period 1 (test drug) + period 2 (reference)\nThe duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
            }, 
            {
                "arm_group_label": "Treatment-Sequence 2", 
                "arm_group_type": "Other", 
                "description": "Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.\nTreatment-sequence 2 : Period 1 (reference) + period 2 (test drug)\nThe duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the bioequivalence of a new transdermal nicotine\n      patch to that of a reference formulation following repeated applications"
        }, 
        "brief_title": "Nicotine Patch - Bioequivalence Study", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Smokers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subject aged 18 to 45 years (inclusive)\n\n          -  Current Smoker of >or = 5 and < or = to 15 cigarettes/day\n\n          -  Fagerstr\u00f6m score < or =5 at selection\n\n          -  Absence of any clinically significant abnormal findings at physical examination,\n             vital sign, Electrocardiogram ECG, biological examinations in the investigator's\n             opinion.\n\n        Exclusion Criteria:\n\n          -  Presence of any significant medical findings or significant history (in particular\n             any cardio-vascular disease, severe renal or hepatic insufficiency, current gastric\n             or duodenal ulcer) that may impact the safety, the interpretation of the results\n             and/or the participation of the subject in the study according to the opinion of the\n             investigator\n\n          -  Any visible skin disorder, abnormal skin pigmentation or dermatologic disease liable\n             to interfere with use or safety assessment of a transdermal patch"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089308", 
            "org_study_id": "V00116 TD 1 06", 
            "secondary_id": "2013-005290-47"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment-Sequence 1", 
                    "Treatment-Sequence 2"
                ], 
                "intervention_name": "Test treatment : V0116 transdermal patch", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment-Sequence 1", 
                    "Treatment-Sequence 2"
                ], 
                "intervention_name": "Reference treatment : Nicotine transdermal patch", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Central Nervous System Agents", 
                "Nicotine polacrilex", 
                "Nicotine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Smoking cessation", 
            "Nicotine", 
            "Tobacco Use Disorder", 
            "Central Nervous System Agents"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gieres", 
                    "country": "France", 
                    "zip": "38610"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "contact_essais_cliniques@pierre-fabre.com", 
            "last_name": "Pierre Fabre M\u00e9dicament"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "During the third application of each period,12 time points up to 24h after the application"
            }, 
            {
                "measure": "Time to Maximum Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "During the third application of each period,12 time points up to 24h after the application"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "During the third application of each period, 12 time points up to 24h after the application"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089308"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pierre Fabre Medicament", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pierre Fabre Medicament", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}